Abstract

  Most of the hospital admitted patients with severe diseases are usually started on intravenous (IV) medications, in particular, those who are released from operation room to intensive care units. Although IV to oral therapy conversion is not suitable for critical patients or those who are unable to absorb orally, there is still a good number of patients in each hospital, who are candidates for the switchover from IV to oral therapy.

Keywords: IV to Oral, Pharamcoeconomic, Switch, Hospitalized

References

1. World Health Day. Antibiotic resistance: No action today, no cure tomorrow (2011).
2. The British Thoracic Society and Public Health Laboratory Service. “Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome”. Quarterly Journal of Medicine 239 (1987): 195-220.
3. Solomkin JS., et al. “Results of a Randomized Trial Comparing Sequential lntravenous/Oral Treatment with Ciprofloxacin Plus Metronidazole to lmipenem/Cilastatin for Intra-Abdominal Infections”. Annuals of Surgery3 (1996): 303-315.
4. Weingarten SR., et al. “Identification of low-risk hospitalized patients with pneumonia for early conversion to oral antimicrobial therapy”. Chest 105 (1994): 1109-1115.
5. Palanisamy A., et al. “Conversion of intravenous to oral antimicrobial therapy in South Indian population”. International Journal of Research in Pharmaceutical and Biomedical Sciences 2 (2011): 1258-1260.
6. Lee SL., et al. “Clinicians’ knowledge, beliefs and acceptance of intravenous to oral antibiotic switching, Hospital Pulau Pinang”. Medical Journal of Malaysia 67 (2012): 190.
7. Product Information: ZANTAC (R) oral tablets, effervescent oral tablets, oral syrup, ranitidine hcl oral tablets, effervescent oral tablets, oral syrup. GlaxoSmithKline, Research Triangle Park, NC (2008).
8. Chau NP., et al. “Ranitidine kinetics in normal subjects”. Clinical Pharmacology and Therapeutics 31 (1982): 770-774.
9. McNeil JJ., et al. “Pharmacokinetics of the H2-receptor antagonist ranitidine in man”. British Journal of Clinical Pharmacology 12 (1981): 411-415.
10. Duggan DE., et al. “Bioavailability of oral dexamethasone”. Clinical Pharmacology and Therapeutics 18 (1975): 205-209.
11. Wilson EA and Brodie MJ. “New antiepileptic drugs”. Bailliere's Clinical Neurology 4 (1996): 723-747.
12. Walker MC and Patsalos PN. “Clinical pharmacokinetics of new antiepileptic drugs”. Pharmacology Therapy 3 (1995): 351-384.
13. Patsalos PN., et al. “The pharmacokinetics of levetiracetam (ucb L059) in patients with intractable epilepsy (abstract 2.72)”. Epilepsia 36 (1995): 52.
14. Regardh CG. “Pharmacokinetics and metabolism of omeprazole in man”. Scandinavian Journal of Gastroenterology 21 (1986): 99-104.
15. Andersson T. “Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole”. Clinical Pharmacokinetics 31 (1996): 9-28.
16. Product Information: PROTONIX (R) delayed-release oral tablets, suspension, pantoprazole sodium delayed-release oral tablets, suspension. Wyeth Pharmaceuticals, Inc, Philadelphia, PA, 2008.
17. Pue MA., et al. “Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects”. European Journal of Clinical Pharmacology 44 (1993): 575-578.
18. Derendorf H., et al. “Pharmacokinetics and oral bioavailability of hydrocortisone”. Journal of Clinical Pharmacology 31 (1991): 473-476.
19. Thakker KM. “Predicting the dose-dependent bioavailability of hydrocortisone and chlorothiazide in humans (letter)”. Journal of Pharmaceutical Sciences 72 (1983): 577.
20. Teich JM., et al. “An information system to promote intravenous-to-oral medication conversion”. Proceedings of the AMIA Symposium (1999): 415-419.
21. Ehrenkranz NJ., et al. “Intervention to discontinue parenteral antimicrobial therapy in hospitalized patients with urinary tract infection, skin and soft tissue infection, or no evident infection”. Infection Control and Hospital Epidemiology 9 (1993): 517-522.
22. Stirling AL., et al. “Experience with a decentralized IV to PO ofloxacin conversion program”. Formulary (1999): 34688-34703.

Citation

Citation: Leena H Saeed., et al. “Early Switch from Intravenous to Oral Therapy in Hospitalized Patients in Neuroscience Center at KFMC: A Cost-minimization Approach". Acta Scientific Medical Sciences 4.11 (2020): 21-26.

Copyright

Copyright: © 2020 Leena H Saeed et al This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.